XNAS · Healthcare · Biotechnology
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
Sol-Gel posted a clear earnings beat, with Q2 EPS of **-$1.13** versus **-$2.31** expected and revenue of **$591K** topping estimates, but the result is still weak given the collapse from last year’s **$17M** base. In biotech, this looks like a non-operationally strong quarter with severely compressed sales and a negative margin.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 | Q2 2026 | -2.31 | -1.13 | +51.08% | $591,000 | ✅ Beat | -0.15% | — | — |
| 2026-05-28 | Q1 2026 | -2.66 | -1.31 | +50.75% | $108,000 | ✅ Beat | -3.25% | -1.21% | -2.36% |
| 2026-03-19 |
| Q4 2025 |
| 0.39 |
| -1.06 |
| -371.79% |
| $696,000 |
| ❌ Miss |
| -0.41% |
| -4.85% |
| -9.59% |
| 2025-11-20 | Q3 2025 | -2.09 | -2.13 | -1.91% | $400,000 | ❌ Miss | — | — | — |
| 2025-08-15 | Q2 2025 | — | 4.17 | — | $17.3M | — | +1.97% | +46.83% | +55.31% |
| 2024-11-15 | Q3 2024 | -0.13 | -0.01 | +92.31% | $5.4M | ✅ Beat | -5.30% | +3.69% | -9.53% |
| 2024-08-16 | Q2 2024 | -0.20 | 0.07 | +135.00% | $5.4M | ✅ Beat | +9.05% | +49.95% | +48.56% |
| 2024-05-20 | Q1 2024 | -0.15 | -0.23 | -53.33% | $466,000 | ❌ Miss | +13.43% | +14.18% | +30.23% |
Showing last 8 quarters.